KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities

This KDIGO Controversies Conference report clarifies how pharmacists should interpret creatinine shifts during guideline-directed heart failure therapy and where evidence in advanced kidney disease remains absent.

📅 Journal publication: Jun 2026 (online Mar 20, 2026) · Last updated: Jul 18, 2026

SGLT2 inhibitorsfinerenoneGLP-1 receptor agonistsARNIRAAS inhibitorsloop diureticsheart failurechronic kidney diseasecardiorenalKDIGO consensusguideline Oncology Pharmacy

Background Information

Preventing kidney damage in cancer treatment requires proactive strategies.

Cancer therapy advancements have improved survival but increased kidney damage risks. Nephrotoxicities occur with chemotherapy, targeted agents, and immunotherapies, affecting treatment and quality of life. Collaboration between oncology and nephrology is crucial to balance cancer treatment effectiveness and kidney health. Proactive kidney monitoring is crucial in patients receiving cancer therapies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Izzedine H, Perazella MA, Kuruvada KM, Jhaveri KD

Citation: Izzedine H, Perazella MA, Kuruvada KM, et al. Cancer therapy and the kidney. Kidney international. 2026;109(6):1125-1136. doi:10.1016/j.kint.2026.01.036

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.